1Kubitza D, Becka M, Wensing G, et al. Safety, phannacodynamics, and pharmacokinetics of BAY 59 - 7939 - an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects [J].Eur J Clin Phannacol, 2005, 61 (12): 873-880.
3Perzbom E, Kubitza D, Misselwitz K Bivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders [J].Hamostaseologie, 2007, 27 (4) : 282 -289.
4Bonnet L, Coker E, Wood L Preventing venous thromboembollsm through risk assessment approaches [J]. Br J Nuts, 2008, 17 (12) : 778 -782.
5Eriksson BI, Borrls LC, Dahl OE, et al A once - daily, oral, direct Factor Xa inhibitor, rivaroxaban ( BAY 59 - 7939), for thromboprophylaxis after total hip replacement [J] . Circulation, 2006, 114 (22) : 2374 - 2381.
6Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short - term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double - blind, randomlsed controlled trial [J]. lancet, 2008, 372 (9632): 31-39.
7Eriksson BI , Borris LC, Friedmsn BJ, et al. Rivamxaban versus enoxaparin for thrombopmphylaxis after hip arthroplasty [J]. N Engl J Med, 2008, 358 (26): 2765-2775.
8Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty [J]. N Engl J Med, 2008, 358 (26): 2776-2786.
9Geerts WH, Bergqvist D, Pineo GF, et al Prevention of venous thromboembolism: American College of Chest Physicians Evidence - Based Clinical Practice Guidelines (8th Edition) [J] . Chest, 2008, 133 (6 Suppl) : 381S -453S.
1Gross PL,Weitz JI.New anticoagulants for treatment of venous thromboembolism[J].Arterioscler Thromb Vasc Biol,2008,28(3):380-386.
2Hirsh J,O'Donnell M,Eikelboom JW.Beyond unfractionated heparin and warfarin:current and future advances[J].Circulation,2007,116(5):552-560.
3Eikelboom JW,Weitz JI.A replacement for warfarin:the search continues[J].Circulation,2007,116(2):131-133.
4Kamali F.Genetic influences on the response to warfarin[J].Curr Opin Hematol,2006,13(5):357-361.
5Schulman S,Henriksson K.Interaction of ibuprofen and warfarin on primary haemostasis[J].Br J Rheumatol,1989,28(1):46-49.
6Hirsh J,Fuster V,Ansell J,et al.American Heart Association/American College of Cardiology Foundation guide to warfarin therapy[J].Circulation,2003,107(12):1692-1711.
7Landefeld CS,Rosenblatt MW,Goldman L.Bleeding in outpatients treated with warfarin:relation to the prothrombin time and important remediable lesions[J].Am J Med,1989,87(2):153-159.
8Hylek EM,Singer DE.Risk factors for intracranial hemorrhage in outpatients taking warfarin[J].Ann Intern Med,1994,120(11):897-890.
9Hylek EM,Evans-Molina C,Shea C,et al.Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation[J].Circulation,2007,115(21):2689-2696.
10Parsi K,Younger I,Gallo J.Warfarin-induced skin necrosis associated with acquired protein C deficiency[J].Australas J Dermatol,2003,44(1):57-61.
